Please login to the form below

Not currently logged in
Email:
Password:

UK biotech

This page shows the latest UK biotech news and features for those working in and with pharma, biotech and healthcare.

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

UK biotech company Synairgen has treated the first patient in a phase 3 trial evaluating its potential COVID-19 treatment SNG001. ... We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right

Latest news

More from news
Approximately 27 fully matching, plus 164 partially matching documents found.

Latest Intelligence

  • A snapshot of… Enterprise Therapeutics A snapshot of… Enterprise Therapeutics

    We tend to experience the same challenges that all small biotech companies do – how do we ensure our therapies have the best chance of making it through to registration against a ... companies. However, it remains to be seen what effects Brexit may

  • A snapshot of Healx A snapshot of Healx

    Healx is based in Cambridge, UK, a key European biotech hub, and was founded in 2014 by Dr Tim Guilliams, a biochemical engineer and founder of the Cambridge Rare Disease Network, ... Why will the company make it in the high-risk, highly competitive

  • A snapshot of Microbiotica A snapshot of Microbiotica

    Why will Microbiotica make it in the high-risk, highly competitive biotech field? ... Of greater concern is the university sector – the UK biotech sector is what it is because of the increasing excellence of the university sector over the last 20 years.

  • Building European biotech firms to rival those of the US Building European biotech firms to rival those of the US

    Richard Mason (pictured above) is a veteran of the UK biotech industry, including a spell as CEO of company XO1 set up by venture capital investors Index Ventures (now Medicxi) in ... In the early days of UK biotech, this often led to major upfront

  • Building Europe’s next breakthrough biotechs Building Europe’s next breakthrough biotechs

    How can the UK life science ecosystem produce even more biotech start-ups, and propel them to long-term success? ... Its founding investors include Cambridge Innovation Capital, Babraham Research Campus through Babraham Bioscience Technologies, Roche's

More from intelligence
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    New CMO to oversee development of lead candidate. UK biotech F-star has appointed Louis Kayitalire, MD, as its new Chief Medical Officer (CMO), wooing him from a senior role in ... F-star says this newly created management position will be crucial

  • Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

    Latest movers in pharma and biotech. Immunocore names new CEO. Bahija Jallal, Immunocore's next CEO. ... Immunotherapy-focused UK biotech company Immunocore has unveiled Bahija Jallal as its new chief executive and director of the board.

  • Redx poaches AstraZeneca senior executive Redx poaches AstraZeneca senior executive

    Lisa Anson joins the UK biotech as its CEO. Drug discovery and development group Redx Pharma has appointed its new chief executive officer in the form of Lisa Anson. ... substantial biotech company built upon an innovative science base, selectively

  • Redx Pharma appoints new chief medical officer Redx Pharma appoints new chief medical officer

    Dr Andrew Saunders joins the UK biotech from Lytix Biopharma. Drug discovery and development group Redx Pharma has appointed Dr Andrew Saunders as its chief medical officer (CMO), a role that ... He joins the UK biotech from Lytix Biopharma, a Norweigan

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Robert Lutz and Dr Jon Roffey join the UK biotech. ... Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.

More from appointments
Approximately 2 fully matching, plus 27 partially matching documents found.

Latest from PMHub

  • Lucid bolsters its senior leadership team

    Shula began working in medical communications in the USA following a successful research career in academia and the biotech industry in the UK, Germany and the USA. ... Coming back to the UK after 13 happy and successful years in America has given me the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics